Skip to content
Review Open access

MicroRNAs in Alcohol-Associated Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease: From Pathogenic Networks and Disease Progression to Precision Biomarkers and Therapeutic Strategies

Oct 2026 · Pharmaceutics · 0 citations · 106 references

TL;DR

The involvement of miRNAs throughout the progression of ALD and MASLD is comparatively examined, with particular emphasis on their roles in lipid metabolic dysregulation, mitochondrial and oxidative stress, autophagic dysfunction, immune activation, hepatocyte death, and hepatic-stellate-cell-associated fibrogenesis.

Abstract

Alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD) arise from distinct etiological factors, but they share a broad spectrum of pathological features during disease progression, including steatosis, oxidative stress, autophagic dysfunction, inflammation, hepatocyte death, and fibrosis. MicroRNAs (miRNAs) are considered important potential post-transcriptional regulators of these processes because of their capacity to coordinately modulate multiple target genes and signaling pathways across diverse hepatic cell populations. In this review, the involvement of miRNAs throughout the progression of ALD and MASLD is comparatively examined, with particular emphasis on their roles in lipid metabolic dysregulation, mitochondrial and oxidative stress, autophagic dysfunction, immune activation, hepatocyte death, and hepatic-stellate-cell-associated fibrogenesis. This review focuses on the role of miRNAs in intercellular communication between hepatocytes, macrophages, neutrophils, and hepatic stellate cells, emphasizing their cell-specific and context-dependent functions in coordinating liver disease progression. Apart from their mechanistic roles, circulating and extracellular-vesicle-associated miRNA signatures have shown great application potential as minimally invasive biomarkers for molecular stratification, disease progression, and precision medicine. Collectively, these findings suggest that miRNAs have broad translational relevance in liver disease. However, their clinical translation remains limited by challenges regarding stability, biodistribution, off-target effects, and cell-type-specific delivery, emphasizing the need for more precise liver-directed therapeutic strategies. These challenges highlight the importance of linking specific miRNA targets with disease stage, cellular source, and appropriate delivery approaches. In this context, the integration of disease etiology, pathological stage, cellular context, miRNA network architecture, biomarker signatures, and delivery technology is essential for evolving miRNAs from mechanistic regulators and biomarkers into precision therapeutic platforms for ALD and MASLD.

Read PDF

Similar papers

Review Oct 2026

MicroRNA Regulatory Networks in Alcohol-Associated Liver Disease: Mechanisms from Steatosis and Inflammation to Fibrosis.

Alcohol-associated liver disease (ALD) is a leading cause of liver-related morbidity and mortality worldwide and progresses through steatosis, alcohol-associated hepatitis, fibrosis, and cirrhosis. MicroRNAs (miRNAs) are established post-transcriptional regulators whose roles in ALD-associated signaling networks have b...

Shi-Hao Du, Dong-Qin Yuan, Qian-Qian Liu et al. · 0 citations
Open access Sep 2026

The Role of NLRP3 Inflammasome in the Pathogenesis and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common chronic liver disease characterized by excessive hepatic lipid accumulation and closely associated with metabolic disorders. Its progression involves not only abnormal lipid metabolism but also inflammatory responses, oxidative stress, mitocho...

Ethan Radu · 0 citations
Review Open access Nov 2026

Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Disease: An Integrated Narrative Review from Molecular Mechanisms to Nutritional and Bioactive Strategies

Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) represents the hepatic manifestation of systemic metabolic dysfunction and serves as an independent risk factor for cardiovascular disease (CVD), the primary cause of mortality in affected individuals. Rather than separate entities,...

Serena Castelli, Gilda Aiello, Fares M. S. Muthanna et al. · 0 citations
Review Open access Sep 2026

Metabolic dysfunction-associated steatotic liver disease: pathogenic mechanisms and exercise-induced molecular adaptations

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a systemic metabolic disorder that spans steatosis, steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. Although hepatic lipid overload is a central pathological feature, MASLD progression is driven by interconnected disturbances in lip...

Sen-Lin Lei, Jia-Sheng Tao, Xiao-An Chen et al. · 0 citations
Review Open access Sep 2026

Multidimensional regulation of hepatic macrophages in chronic liver disease: from metabolic reprogramming to intercellular and interorgan crosstalk

Chronic liver diseases (CLDs), including metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD, viral hepatitis, liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC)), impose enormous global public health burdens. Hepatic macrophages act as core orchestrators go...

Cheng-Hao Xu, Xin-Yu Zhu, Hai-Na Xie et al. · 0 citations
Review Sep 2026

The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease and Associated Hepatocellular Carcinoma: Pathogenesis and Therapeutic Interventions.

Metabolic dysfunction-associated steatotic liver disease (MASLD) comprises a spectrum of liver diseases from simple steatosis to metabolic dysfunction-associated steatohepatitis and its associated fibrosis, cirrhosis, and MASLD-associated hepatocellular carcinoma (MASLD-HCC). MASLD affects over one-third of the global...

Huai Qian, Xiao-Lei Li, Hua Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.